| |
著者: Angela Dispenzieri, Francis Buadi, Shaji K Kumar, Craig B Reeder, Tamur Sher, Martha Q Lacy, Robert A Kyle, Joseph R Mikhael, Vivek Roy, Nelson Leung, Martha Grogan, Prashant Kapoor, John A Lust, David Dingli, Ronald S Go, Yi Lisa Hwa, Suzanne R Hayman, Rafael Fonseca, Sikander Ailawadhi, P Leif Bergsagel, Ascher Chanan-Khan, S Vincent Rajkumar, Stephen J Russell, Keith Stewart, Steven R Zeldenrust, Morie A Gertz
雑誌名: Mayo Clin Proc. 2015 Aug;90(8):1054-81. doi: 10.1016/j.mayocp.2015.06.009.
Abstract/Text
Immunoglobulin light chain amyloidosis (AL amyloidosis) has an incidence of approximately 1 case per 100,000 person-years in Western countries. The rarity of the condition not only poses a challenge for making a prompt diagnosis but also makes evidenced decision making about treatment even more challenging. Physicians caring for patients with AL amyloidosis have been borrowing and customizing the therapies used for patients with multiple myeloma with varying degrees of success. One of the biggest failings in the science of the treatment of AL amyloidosis is the paucity of prospective trials, especially phase 3 trials. Herein, we present an extensive review of the literature with an aim of making recommendations in the context of the best evidence and expert opinion.
Copyright © 2015 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.
PMID 26250727 Mayo Clin Proc. 2015 Aug;90(8):1054-81. doi: 10.1016/j.mayocp.2015.06.009.
|
